Loading data…
Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.
$79.92M net income for the year ended December 31, 2025. These are reported results, not a forecast or a stock recommendation.
Latest-filed standard financial facts · USD
Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.
Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.
| Reported period | Reported value | Filed | Source |
|---|---|---|---|
| January 1, 2025 – December 31, 2025 | $373,259,000 | April 29, 2026 | 20-F ↗ |
| January 1, 2024 – December 31, 2024 | $356,333,000 | April 24, 2025 | 20-F ↗ |
| January 1, 2023 – December 31, 2023 | $464,049,000 | April 24, 2024 | 20-F ↗ |
| January 1, 2022 – December 31, 2022 | $449,511,000 | April 24, 2023 | 20-F ↗ |
| January 1, 2021 – December 31, 2021 | $673,680,000 | April 6, 2022 | 20-F ↗ |
| January 1, 2020 – December 31, 2020 | $506,639,000 | April 30, 2021 | 20-F ↗ |
| January 1, 2019 – December 31, 2019 | $487,203,000 | April 24, 2020 | 20-F ↗ |
| January 1, 2018 – December 31, 2018 | $478,455,000 | April 25, 2019 | 20-F ↗ |
One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.
Concept: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · Retrieved October 14, 2026
Response SHA-256: 31348aaff570a1d3552c8d9744025ac5a369f2bfd9f86af455a72c938304a653
Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.